New clinical data on Almirall’s biologics portfolio demonstrates further opportunities to positively impact patients and the medical community· New data to be presented on ...
Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...
Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...
The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...
Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older ...
GlobalData on MSN5d
Aclaris doses first subject in Phase IIa atopic dermatitis treatment trialAclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...
The Asian Parent on MSN9d
Atopic Dermatitis in Kids: What Every Parent Should KnowAtopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...
Roflumilast cream 0.15% was well tolerated and significantly improved symptoms in adults and children with mild to moderate atopic dermatitis (AD) in two phase 3 trials. The two phase 3 randomized ...
Researchers investigated the correlation between serum levels of interleukin-31 (IL-31) and CCL17, as well as cutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback